FTC Proposes Settlement With Express Scripts Over Insulin Pricing
February 12, 2026
February 12, 2026
WASHINGTON, Feb. 12 (TNSFR) -- The Federal Trade Commission announced a proposed consent agreement to resolve allegations that Express Scripts Inc., St. Louis, Missouri, and its affiliates engaged in anticompetitive practices that inflated insulin prices. The settlement addresses charges that the pharmacy benefit manager prioritized high-list-price drugs to secure larger rebates, often at the expense of patient affordability.
Under the terms of the agreement, the organization must i . . .
Under the terms of the agreement, the organization must i . . .